Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

TOGETHER, 0

metformin (n=217) vs. placebo (n=206)

randomized controlled trial   risk of bias NA

Studied treatment

Metformin 750mg dose twice daily for 10 days

Control treatment

placebo

Patients

COVID 19 outpatients

Method

double-blind

Brazil

Remark

unpublished results; metformin inclusion were interrupted in this platform trial

COVID-OUT (metformin), 2022 NCT04510194

metformin (n=663) vs. placebo (n=660)

randomized controlled trial   some concerns about risk of bias

Studied treatment

immediate-release metformin administered with an increase in dose over 6 days to 1500 mg per day for 14 days,

Control treatment

placebo

Patients

COVID 19 outpatients

Method

double-blind

US, 6 centres

2-by-3 factorial design (metformin, ivermectin, and fluvoxamine)

Remark